Literature DB >> 2272771

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

N J Vogelzang1, V J Lanzotti, B Muntean, R R Blough.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2272771     DOI： 10.1007/bf00171845

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  4 in total

1.  Response criteria for the prostate of the USA National Prostatic Cancer Project.

Authors:  G P Murphy; N H Slack
Journal:  Prostate       Date:  1980       Impact factor: 4.104

2.  Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma.

Authors:  R F Marschke; L K Kvols; S A Cullinan; J A Laurie; J A Mailliard; L K Tschetter; M J O'Connell
Journal:  Med Pediatr Oncol       Date:  1988

3.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

4.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).

Authors:  D D Von Hoff; J W Myers; J Kuhn; J F Sandbach; R Pocelinko; G Clark; C A Coltman
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.